These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1155 related articles for article (PubMed ID: 27435662)

  • 1. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
    Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
    Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of leucine-rich-repeat-containing G-protein-coupled receptor 5, an intestinal stem cell marker, in gastric carcinomas.
    Jang BG; Lee BL; Kim WH
    Gastric Cancer; 2016 Jul; 19(3):767-77. PubMed ID: 26386561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical Expression of CD133 and LGR5 in Ulcerative Colitis-associated Colorectal Cancer and Dysplasia.
    Kazama S; Kishikawa J; Tanaka T; Hata K; Kawai K; Nozawa H; Ishihara S
    In Vivo; 2019; 33(4):1279-1284. PubMed ID: 31280219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
    Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
    Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear Notch3 expression is associated with tumor recurrence in patients with stage II and III colorectal cancer.
    Ozawa T; Kazama S; Akiyoshi T; Murono K; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Yamaguchi H; Ishihara S; Sunami E; Kitayama J; Morikawa T; Fukayama M; Watanabe T
    Ann Surg Oncol; 2014 Aug; 21(8):2650-8. PubMed ID: 24728738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
    Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
    Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
    Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
    Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
    Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
    Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis.
    Nagata H; Ishihara S; Kishikawa J; Sonoda H; Murono K; Emoto S; Kaneko M; Sasaki K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Hata K; Kawai K; Nozawa H
    Int J Oncol; 2018 Mar; 52(3):721-732. PubMed ID: 29328371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
    Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
    Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
    de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
    Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
    Gao FJ; Chen JY; Wu HY; Shi J; Chen M; Fan XS; Huang Q
    Int J Clin Exp Pathol; 2014; 7(4):1572-9. PubMed ID: 24817953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.